Dermatitis

WEDNESDAY, Nov. 20, 2024 -- The patch test positivity rate varies from 13 to 100 percent for cosmetic products, and predominant allergens in cosmetics include nickel sulfate and fragrance mix I, according to a review published in the November issue of SKIN.Trya Oktaviani, M.D., from Universitas Sebelas Maret in Surakarta, Indonesia, and colleagues conducted a systematic review to determine the list of allergens that most often cause allergic contact dermatitis in cosmetic products and to examine the patch test positivity rate for cosmetic products. Thirteen studies were included, with 111,097 participants: 10 retrospective studies and three clinical trials performed in various locations.The researchers found that the patch test positivity rate varied from 13 to 100 percent. Nickel sulfate, fragrance mix I, cobalt chloride, para-phenylenediamine base, potassium dichromate, and balsam of Peru were the predominant allergens identified in cosmetics."This systematic review contributes meaningful insights into the prevalence and allergen profiles of cosmetic-induced contact dermatitis," the authors write. "Identifying key allergens, such as nickel sulfate and fragrance mix I, emphasizes the importance of targeted interventions and increased awareness within the cosmetics industry."

Predominant allergens identified in cosmetics include nickel sulfate, fragrance mix I, cobalt chloride, para-phenylenediamine base

Patch Test Positivity Rate Varies From 13 to 100 Percent for Cosmetics

<div class="raw-html-embed"><mux-player playback-id="G7YF5psNtub5eoT53jnfddJCkT5Ha2UmBDI01y00XkQfY" env-key="ENV_KEY" metadata-video-title="ZORYVE FOAM" controls=""></mux-player></div>Dr James Q Del Rosso announces the launch of roflumilast topical foam, 0.3%, for seborrheic dermatitis, discussing the versatility and efficacy of this landmark treatment<o:p></o:p>Arcutis Biotherapeutics, Inc., has received FDA approval for ZORYVE (roflumilast) topical foam, 0.3%, a game-changing treatment for seborrheic dermatitis in patients 9 years and older. The once-daily, steroid-free foam showcases rapid disease clearance, a substantial itch reduction, and unique application versatility.&nbsp;Seborrheic dermatitis challenges addressed&nbsp;Dermatology experts commend the approval, recognizing the long-standing challenges associated with seborrheic dermatitis. Patients often faced difficulties achieving disease clearance, adhering to treatment regimens, and addressing safety concerns with prolonged use. The foam offers a once-daily application, is steroid-free, and is the first drug approved for seborrheic dermatitis with a new mechanism of action in over 2 decades.&nbsp;Clinical trial insights&nbsp;The pivotal Phase 3 STRATUM trial showcased ZORYVE's performance, with results demonstrating rapid disease clearance by Week 2, significant itch relief within 48 hours, and 50.6% of patients achieving complete clearance at Week 8.&nbsp;Nearly 80% of participants achieved Investigator Global Assessment (IGA) Success by Week 8 (79.5% ZORYVE foam vs 58.0% vehicle; P&lt;0.0001). IGA Success was defined as an IGA score of “Clear” (0) or “Almost Clear” (1), plus a 2-grade IGA score improvement from baseline at Week 8.&nbsp;The study also underlined ZORYVE's impact on secondary endpoints, including improvements in itch, scaling, erythema, and patient-reported outcomes measured by the Dermatology Life Quality Index.&nbsp;Future outlook&nbsp;The FDA's approval of ZORYVE marks a significant milestone in dermatology, offering a highly effective and versatile solution for seborrheic dermatitis that addresses longstanding challenges and improves the overall quality of life for millions of affected individuals.&nbsp;Arcutis plans to launch ZORYVE foam by the end of January 2024, making it widely available through key wholesaler and dermatology pharmacy channels.

Breakthrough approval revolutionizes seborrheic dermatitis treatment

LAUNCH ALERT: FDA Approves Roflumilast Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis

In Episode 51 of Derms and Conditions, our host James Q. Del Rosso, DO, sits down with Matt Zirwas, MD, a dermatologist in Columbus, Ohio and founder of the Bexley Dermatology Research Clinic. The two discuss how to approach a patient with an unspecified dermatitis.

In Episode 51 of Derms and Conditions, our host James Q. Del Rosso, DO, sits down with Matt Zirwas, MD, a dermatologist in Columbus, Ohio and founder of the Bexley Dermatology Research Clinic. The two discuss how to approach a patient with an unspecified dermatitis.Dr. Zirwas begins by recounting his experiences with dermatitis unspecified, also known as non-atopic adult dermatitis, and how he became interested in treating this complex disease. Dr. Del Rosso asks how to differentiate between this disease and other similar diagnoses, prompting Dr. Zirwas to share his algorithm for recognizing the many types of eczema and contact dermatitis.Patients that receive this diagnosis often want to know what caused it and how it can be prevented. While the answer is not always clear, Dr. Zirwas provides his tips for counseling patients on possible triggers. This can include the food that they eat and its effect on the microbiome, as well as the many products they apply to their skin. Dr. Zirwas has plenty of suggestions for products with low allergenicity that these patients can try.Finally, the two discuss the role nickel plays in contact dermatitis and how to differentiate between atopic dermatitis, allergic contact dermatitis, and irritant contact dermatitis. This episode is full of pearls for one of the trickiest diagnoses in dermatology, so tune in to learn more!

Dermatitis Condition Center

Featured in Dermatitis

Dermatitis Episodes to Explore

Thinking Through Diagnostic Challenges in Patients with Eczema: Considerations and Pitfalls Part 1

Dermatitis News & Research